Abstract
We evaluated treatment with linezolid, dosed at 800 mg once daily for 1 to 4 months as guided by sputum culture status and tolerance and then at 1,200 mg thrice weekly until ≥ 1 year after culture conversion, in addition to individually optimized regimens among 10 consecutive patients with extensively drug-resistant tuberculosis or fluoroquinolone-resistant multidrug-resistant tuberculosis. All achieved stable cure, with anemia corrected and neuropathy stabilized, ameliorated, or avoided after switching to intermittent dosing. Serum linezolid profiles appeared better optimized.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetamides / administration & dosage*
-
Acetamides / therapeutic use
-
Adult
-
Antitubercular Agents / administration & dosage*
-
Antitubercular Agents / therapeutic use
-
Drug Administration Schedule
-
Female
-
Humans
-
Linezolid
-
Male
-
Middle Aged
-
Mycobacterium tuberculosis / drug effects*
-
Oxazolidinones / administration & dosage*
-
Oxazolidinones / therapeutic use
-
Sputum / microbiology
-
Treatment Outcome
-
Tuberculosis, Multidrug-Resistant / drug therapy*
-
Young Adult
Substances
-
Acetamides
-
Antitubercular Agents
-
Oxazolidinones
-
Linezolid